Tag: Bioventus

Bioventus launches OSTEOMATRIX biphasic bone graft

  Bioventus has launched OSTEOMATRIX+, a biphasic bone graft for use in bone remodelling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a mouldable bone graft substitute...
Viscogliosi

Bioventus enters into definitive agreement to divest BMP development programme to...

Bioventus has entered into a definitive agreement to divest its next-generation bone morphogenetic protein (BMP) development programme to a new company formed by Viscogliosi...

Bioventus announces new executive appointments

Bioventus has announced two changes to its executive leadership team. Greg Anglum has been promoted to senior vice president and chief financial officer. Anthony...

Premier US healthcare improvement company to offer Bioventus’ full surgical portfolio

Bioventus has announced that its full surgical orthobiologics portfolio is now available through Premier, a US health care improvement company comprised of 3,750 US...

Bioventus to invest in new clinical research for Exogen

Bioventus is to commission an innovative series of real-world evidence, direct-to-patient studies to validate the ability of its Exogen ultrasound bone-healing system to mitigate...

John Nosenzo appointed chief commercial officer of Bioventus

Bioventus has named John Nosenzo as chief commercial officer. Nosenzo has worked in sales and marketing in the pharmaceutical and medical diagnostics areas markets...